Genomic and molecular characterization of esophageal squamous cell carcinoma. by Lin, De-Chen et al.
UCLA
UCLA Previously Published Works
Title
Genomic and molecular characterization of esophageal squamous cell carcinoma.
Permalink
https://escholarship.org/uc/item/9ms7n83b
Journal
Nature genetics, 46(5)
ISSN
1061-4036
Authors
Lin, De-Chen
Hao, Jia-Jie
Nagata, Yasunobu
et al.
Publication Date
2014-05-01
DOI
10.1038/ng.2935
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Genomic and molecular characterization of esophageal 
squamous cell carcinoma
De-Chen Lin1,2,8,9, Jia-Jie Hao3,8, Yasunobu Nagata4,8, Liang Xu2,8, Li Shang3, Xuan Meng2, 
Yusuke Sato4, Yusuke Okuno4, Ana Maria Varela2, Ling-Wen Ding2, Manoj Garg2, Li-Zhen 
Liu2, Henry Yang2, Dong Yin5, Zhi-Zhou Shi3, Yan-Yi Jiang3, Wen-Yue Gu3, Ting Gong3, Yu 
Zhang3, Xin Xu3, Ori Kalid6, Sharon Shacham6, Seishi Ogawa4, Ming-Rong Wang3,9, and H. 
Phillip Koeffler1,2,7
1Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los 
Angeles, USA
2Cancer Science Institute of Singapore, National University of Singapore, Singapore
3State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical 
College and Chinese Academy of Medical Sciences, Beijing, China
4Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
5Medical Research Center, Sun Yat-Sen Memorial Hospital, Guangzhou, China
6Karyopharm Therapeutics, Natick, MA, USA
7National University Cancer Institute, National University Hospital Singapore, Singapore
Abstract
Esophageal squamous cell carcinoma (ESCC) is a world-wide prevalent cancer, which is 
particularly common in certain regions of Asia. Here we report the whole-exome or targeted deep 
sequencing of 139 paired ESCC cases, and analysis of somatic copy number variations (SCNV) of 
over 180 ESCCs. We identified novel significantly mutated genes such as FAT1, FAT2, ZNF750 
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and KMT2D, in addition to previously discovered ones (TP53, PIK3CA and NOTCH1). Further 
SCNV evaluation, immunohistochemistry and biological analysis suggested their functional 
relevance in ESCC. Notably, RTK-MAPK-PI3K pathways, cell cycle and epigenetic regulation 
are frequently dysregulated by multiple molecular mechanisms in this cancer. Moreover, our 
approaches uncovered many novel druggable candidates, and XPO1 was further explored as a 
therapeutic target because of its mutation and protein overexpression. Together, our integrated 
study unmasks a number of novel genetic lesions in ESCC and provides an important molecular 
foundation for understanding esophageal tumors and developing therapeutic targets.
ESCC is one of the most common malignant diseases in the world and especially in China, 
where it is the fourth most common cause of cancer-related deaths1. Unlike cancers that 
have been extensively studied, such as breast and colon cancers, the outcome of ESCC 
remains unchanged during the last several decades, with a five-year survival rate ranging 
from 15% to 25%2. We and others have revealed frequent somatic copy number variations 
(SCNV) involving 3q263, 9p214, 11q13.35 and 8q24.36, as well as somatic mutations in 
PIK3CA7, TP538and NOTCH18 in ESCC. However, in general, understanding of the 
genomic abnormalities in this disease is limited to studies of small size of cohorts4,6,7,9-12, 
including a recent whole-exome sequencing approach of 12 ESCCs8. Thus, a compelling 
need exists to extensively identify genomic abnormalities underlying ESCC, for elucidating 
its molecular basis and guiding the development of effective targeted therapies.
We firstly sequenced whole exomes (WES) of 20 paired ESCC germline/tumors (Discovery 
Cohort, mean coverage 79×, Supplementary Tables 1a, 2a). Transcriptome sequencing 
(RNA-seq) was also performed on 4 of these 20 tumors. A total of 1,186 non-silent somatic 
mutations (affecting 1,042 genes) were identified (Supplementary Table 3), a mutation rate 
comparable to those of most adult solid tumors13 (Supplementary Fig. 1). We extensively 
validated 362 candidate somatic mutations with Sanger sequencing (True positive rate = 
93.1%, Supplementary Table 3). Intratumoral clonality analysis showed that both biclonal 
and multiclonal signatures existed in ESCC (Supplementary Fig. 2). Cross comparing the 
WES with RNA-seq data from the same tumors revealed that 61% of the mutated genes 
were transcribed (Supplementary Table 4), which is comparable to the value reported on 
breast cancer14.
To evaluate the prevalence of these mutated genes from Discovery Cohort, we sequenced all 
of their coding exons with 119 additional matched ESCC germline/tumors, as well as 10 
ESCC cell lines (Frequency Cohort, mean coverage 111×, Supplementary Tables 1b, 2b). To 
cover more comprehensively the mutational events in this disease, we also included an 
additional 277 genes which were discovered in the previous WES study of 12 ESCCs8 
and/or were causally implicated in other human cancers (Cancer Gene Census; see URLs; 
Supplementary Table 5). As a result, a total of 1,847 non-silent somatic mutations were 
identified with an average of 15 mutations per case (True positive rate = 96.2%, Fig. 1a; 
Supplementary Table 6). Remarkably, mutational spectrums revealed from Discovery and 
Frequency Cohort are almost identical (Supplementary Fig. 3a), suggesting that our targeted 
sequencing approach comprehensively unmasked most of the mutational events in DNA 
coding regions in ESCC. Of note, trinucleotide signature analysis suggested that DNA 
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cytidine deaminase APOBEC3B is responsible for ESCC mutagenesis15-17 (Fig. 1b, 
Supplementary Fig.3b), and indeed, APOBEC3B expression was clearly up-regulated in 
ESCC tumors (Fig. 1c). We observed that 609 genes were mutated in 2 or more samples, 
with 62 genes mutated at a frequency over 5% (Supplementary Fig. 3c). To identify 
mutations conferring selective growth advantages (“Driver Mutations”), we applied the 
algorithm MutSigCV13, which corrects for variation by incorporating patient-specific 
mutational spectrum, gene-specific background mutational burden and also by measuring 
gene expression level and replication time. As a result, we calculated that 13genes were 
significantly mutated (False discovery rate q < 0.2). Importantly, many of these significantly 
mutated genes had not previously been implicated in ESCC.
To interrogate SCNV in ESCC, we examined 22 tumors with SNP-array (18 from Discovery 
Cohort), as well as 59 samples with array-CGH18. We further comprehensively analyzed 
three additional SNP-array datasets measuring primary ESCCs4,11,12 (Supplementary Table 
7), resulting in a total of 184 analyzable primary ESCC samples. We focused on focal 
SCNV, defined as narrow regions (typically <100 kb) exhibiting high-amplitude of copy 
number changes (Online Methods), which has more probability to contain cancer genes. 
This approach identified 14 recurrent focal SCNVs, with the most frequent amplification 
peak spanning the CCND1 gene on 11q13.2 (Supplementary Table 7). Additional peaks 
involving important cancer genes such as EGFR, MYC, KRAS and CDKN2Awere found. 
Notably, FGFR1 was shown to be frequently amplified, which has not been reported before 
in ESCC. To confirm this observation, we examined an additional 53 ESCC tumors with 
fluorescence in situ hybridization (FISH) and found that FGFR1 was amplified in 11 
samples (Fig. 2a; Supplementary Table 7). Furthermore, with immunohistochemistry (IHC), 
we found that the FGFR1 protein was up-regulated in 17.3% ESCC tumors (Fig. 2b; 
Supplementary Table 8a). Given that FGFR amplification predicts for sensitivity to targeted 
inhibitors in several other solid tumors19, our results suggest that FGFR1 is a potential 
therapeutic target in ESCC.
We next sought to understand dysregulated pathways in ESCC. As we previously reported 
protein alterations in ESCC using meta-analysis20, here we also took into account protein 
overexpression evidence. Mitogen-activated protein kinase (MAPK) (Fig. 2d, P = 0.0005, 
Supplementary Table 9a, Online Methods) and phosphatidylinositol 3-kinase 
(PI3K)pathways (P = 0.0004) are augmented by multiple mechanisms: i) amplification and 
overexpression of RTKs, KRAS and PIK3CA; ii) activation mutations of ERBB4 and 
PIK3CA; iii) inactivation mutations of PTEN, MAP3K13 and MAP3K15. In addition, IL7R 
amplification and JAK1 mutations were identified, which will likely activate JAK-STAT3 
signaling (P=0.0006). Supportively, we have shown that p-STAT3 was elevated in ESCC21, 
which transforms esophageal epithelial cells cooperatively with amplified SOX222. Cell 
cycle progression (Fig. 2e, P = 1.63E-05) is altered mostly by CCND1 amplification, 
CDKN2A deletion/mutation and TP53 mutation. As a negative regulator of c-Myc, frequent 
FBXW7 mutations were observed in our investigation (Fig. 2c), confirming a recent report of 
this gene in ESCC8. Importantly, we next examined FBXW7 protein expression with IHC 
and found its mutation led to loss of the protein (Fig. 2c). Moreover, in an additional cohort 
(n = 40), we determined that FBXW7 protein was down-regulated in 33% tumors 
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(Supplementary Fig.7; Supplementary Table 8b), further demonstrating its relevance in 
ESCC. Another prominent enrichment of mutated genes in ESCC are those implicated in 
epigenetic modifications (P = 0.0013, Fig. 2f, Supplementary Table 9b), such as members of 
SWI/SNF complex (ARID2 and PBRM1), histone methyltransferases KMT2D and KMT2C, 
and demethylase KDM6A.
ZNF750 is a poorly studied nuclear protein that is up-regulated in differentiated skin 
keratinocytes23,24. We observed that ZNF750 was significantly mutated in ESCC (q = 
1.24E-06, Fig. 3a). Strikingly, analysis of public datasets revealed that ZNF750 is largely 
mutated in squamous cell carcinomas, with most of them presenting truncating mutations 
(Supplementary Fig. 4b). Supportively, ESCC harbors a much higher mutational burden 
affecting ZNF750 than esophageal adenocarcinoma. The similar pattern was also observed 
when comparing lung SCC to lung adenocarcinoma. From Cancer Cell Line Encyclopedia 
(CCLE, see URL) results, we found that ZNF750 mRNA was expressed at a much higher 
level in ESCC and UASCC than any other non-squamous cancer cell lines (Supplementary 
Fig. 4a). These data suggest that ZNF750 somatic mutations are biologically relevant in 
squamous cell malignancy. In addition, we identified that ZNF750 was focally deleted in 
3.4% ESCC tumors (Fig. 3b) and ZNF750 mRNA level was significantly under-expressed in 
esophageal tumors compared with normal tissue (Fig. 3c). Moreover, our IHC approach 
showed that in normal esophageal epithelial, ZNF750 protein displayed strong nuclear 
staining in the suprabasal layer of cells and above; whereas in ESCC tumors, ZNF750 was 
expressed at much lower levels (Fig. 3d; Supplementary Table 8c). Importantly, in ESCC 
cells with wildtype endogenous ZNF750 expression, depletion of ZNF750 promoted cell 
proliferation (Fig. 3e), associated with a decreased expression of the genes implicated in late 
epithelial differentiation, whereas ectopic expression of ZNF750 led to the up-regulation of 
these genes (Supplementary Fig. 4c). Moreover, 12-O-tetra-decanoylphorbol-13-acetate 
(TPA), a well-characterized differentiation-induction agent which has also been commonly 
used to promote ESCC differentiation25,26, markedly enhanced ZNF750 expression (Fig. 
3f), with a concomitant inhibition of cell proliferation (Supplementary Fig. 4d). Notably, 
ectopic expression of ZNF750 further promoted the TPA-induced growth-suppression (Fig.
3g). Collectively, these results indicate that ZNF750 might function as a novel tumor 
suppressor in ESCC through regulating squamous cell differentiation.
FAT family is comprised of FAT1, FAT2, FAT3 and FAT4, which are cadherin superfamily 
members homologous to Drosophila gene fat. Very recently, FAT1has been reported as a 
tumor suppressor in glioblastoma, colorectal cancer and HNSCC27. However, the precise 
role of FAT genes in cancer still remains inconclusive and needs further 
characterization28,29. Our data revealed that ESCC harbored very frequent, mutually-
exclusive truncating mutations affecting FAT1, FAT2 and FAT3 compared to other solid 
tumors (Figs. 4a-b, Supplementary Fig. 5a). Among FAT1-mutated tumors, two samples 
were also analyzed with SNP-array, and we discovered loss of heterozygosity of the FAT1 
gene in both tumors (Supplementary Fig.5b), supporting Knudson's two-hit model. We next 
found that homozygous deletions ofFAT1 occurred in 3.4% ESCCs (Fig. 4c). Furthermore, 
IHC staining demonstrated that FAT1 protein expression was down-regulated in ESCC (Fig. 
4d). To study the function of FAT gene inactivation in ESCC, we first silenced wildtype 
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FAT1 expression with siRNA, and observed increase in cell proliferation (Fig. 4e). On the 
other hand, ectopic expression of FAT1 cDNA27 significantly inhibited both cell 
proliferation and colony formation in soft agar (Supplementary Fig. 6). Importantly, 
depletion of FAT2 with shRNA promoted ESCC growth in vivo (Figs. 4f-g). Together, these 
genetic/expression alterations and biological evidence strongly suggest that FAT1 and FAT2 
likely encode tumor suppressors which are frequently disrupted in ESCC.
In mammalian cells, the chief mediator of protein nuclear export is exportin 1 (XPO1).Due 
to its ability to export a number of tumor suppressors, targeting XPO1 has been considered 
as an anti-neoplastic approach30. We found one missense mutation D624G affecting XPO1. 
Importantly, this mutation is identical to the one discovered in chronic lymphocytic 
leukemia31. Structural modeling analysis revealed that Asp624 is part of the binding sites of 
its conventional cargo, such as Snurportin32,33, forming a salt bridge with Snurportin's 
Lys144 (Fig. 5a). D624G mutation presumably reduces the affinity of interactions due to 
loss of the salt bridge. This alteration may accelerate the turnover of XPO1 from “bound” to 
“unbound” state and enhance its exporting efficiency. We next analyzed the expression 
levels of XPO1's mRNA and protein and found that they were frequently overexpressed in 
ESCC tumor samples (Figs. 5b-c). Moreover, XPO1 overexpression positively correlated 
with larger tumor size (P = 0.016, Supplementary Table 8d). Notably, the XPO1-mutated 
tumor also showed up-regulated protein level compared with the matched adjacent normal 
esophageal epithelium, indicating a gain-of-function phenotype (Fig. 5b). We next silenced 
XPO1 gene expression with shRNA, and noticed the induction of apoptosis (as evidenced by 
cleaved-PARP) and retardation of cell proliferation (Figs. 5d, e).To explore whether XPO1 
is druggable in ESCC, we treated ESCC cells with a novel oral, small-molecule inhibitor, 
KPT-330, which specifically blocks its function by binding to the active site Cys52834-36. 
Submicromolar concentrations of KPT-330 inhibited ESCC cell proliferation and induced 
significant apoptosis (Figs. 5f, g). Inhibition of XPO1 with either shRNA or KPT-330 
altered the expression of its known cargos (such as P53), as well as indirect targets including 
Cyclin D1, c-Myc, PUMA and BIM, which might be due to various novel mechanisms that 
we and others have recently identified37-43 (Figs. 5e, h). Given that frequent overexpression 
of XPO1 protein is clinically relevant44-47 and functionally contributes to the cellular 
malignant phenotype, targeting XPO1 in those patients with XPO1 up-regulation might offer 
potential benefits in ESCC.
In an effort to identify comprehensively therapeutic targets in ESCC, we correlated genomic 
mutations, amplifications, and mRNA/protein up-regulations48-51 in both primary tumors 
and cancer cell lines, with novel targeted therapeutic approaches. We chose those targeting 
approaches that have been approved for clinical use52,53 or are under evaluation in clinical 
trials (see URL). As a result, we identified 31 genes with potentially actionable alterations in 
ESCC. Recurrent candidate druggable targets included ERBB, HDAC and PI3K family, 
XPO1, FGFR1, TP53, JAK-STAT3 and MTOR-RPS6K signaling (Supplementary Table 
10). Importantly, most of the targets and pathways discovered here have not previously been 
considered as actionable targets in ESCC. These results suggest that many novel potential 
therapeutic targets exist in ESCC that need further investigation.
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In summary, we report the mutational landscape of 139 ESCCs as well as SCNV overview 
of 184 ESCC cases. A number of novel mutated/altered genes and pathways were identified 
with statistical and biological evidence of growth selection, indicating that they likely 
contribute to esophageal tumorigenesis. Together with XPO1, our analysis proposes many 
potential therapeutic targets, which offer opportunities to address a typically chemo-resistant 
cancer.
Online Methods
Sample collection and histopathological assessment
ESCC tissue samples were collected from Cancer Institute/Hospital, Chinese Academy of 
Medical Sciences (CAMS) and Linxian Cancer Hospital. All the samples used in this study 
were residual specimens collected after diagnosis. No patient received treatment before 
sample collection. Matched normal tissues (germline controls) were collected from adjacent 
esophageal epithelial five centimeters away from the border of surgical area. All tumor/
normal samples were subject to hematoxylin staining and histopathological review to assess 
the presence of tumor cells, normal esophageal epithelial cells, lymphocytic infiltration and 
necrotic cells. Tumor cellularity was scored visually in a semi-quantitative fashion and only 
those with >70% malignant cells were chosen for DNA/RNA sequencing. All patients 
signed independent informed consent forms for the sampling and molecular analyses. This 
study has been approved by the Ethics Committee/IRB of Cancer Institute/Hospital, CAMS 
and Linxian Cancer Hospital.
Cell culture and related chemicals
All of the human ESCC cell lines and 293T were grown in Dulbecco modified Eagle 
medium (DMEM) with 10% fetal calf serum (FCS) and were maintained at 37°C in a 5% 
CO2 air humidified incubator. ESCC cell lines KYSE30, KYSE50, KYSE70, KYSE110, 
KYSE150, KYSE450, KYSE510 and YES2 were kindly shared by Yutaka Shimada 
(Faculty of medicine, Kyoto University). KYSE140 and KYSE180 were generously 
provided by Dr. Xin-Yuan Guan. All ESCC cell lines were regularly authenticated and 
tested for absence of mycoplasma recently55. TPA was purchased from Sigma-Aldrich. 
KPT-330 was provided by Karyopharm Therapeutics.
Short-term cell proliferation assays
Cells were placed into 96-well plates at 2-4 × 103 cells/well and incubated for an additional 
4-5 days in DMEM with 1% - 10% FCS. The MTT (3-(4, 5-dimethylthiazol–2-yl) -2, 5-
diphenyl tetrazolium bromide) assay was performed as described previously56.
Assessment of apoptosis
Annexin V assay (BD Pharmingen) was performed to assess apoptosis according to the 
manufacturer's instructions. Briefly, cells were harvested after exposure to KPT-330, washed 
twice with PBS, incubated with FITC/PE-conjugated Annexin V and propidium iodide/7-
AAD for 15 min, and measured by flow cytometry (FCM) using FACScan (Becton 
Dickinson).
Lin et al. Page 6
Nat Genet. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Xenografts in NOD/SCID mice
Gender-matched NOD/SCID mice were provided by Cancer Science Institute of Singapore 
at 5-6 weeks of age. 2×106 of KYSE150 cells (Scramble and shFAT2 stable cells) were 
mixed with 100 μl of Matrigel solution (BD Biosciences) per injection; and the mixture was 
injected subcutaneously on the upper flanks of NOD/SCID mice. Mice were randomly 
allocated to either Scramble or shFAT2 groups. After 19 days, the mice were sacrificed to 
weigh and analyze the dissected tumors. No blinding of investigators was performed. No 
statistical methods were used to determine the sample size of mice. Animal study was done 
in compliance with ethical regulations of relevant Institutional Animal Care and Use 
Committee.
Reverse transcription and Real-time PCR
Total RNA was reverse transcribed to cDNA with Superscript III (Invitrogen) according to 
manufacturer's protocols. Real-time PCR reactions were performed in triplicates for every 
sample in 7500 Real-time PCR System (Applied Biosystems). Primers are listed in 
Supplementary Table 13a.
Lentiviral based expression and shRNA vectors
The open reading frame (ORF) of human FAT1 and ZNF750 transcripts were generously 
provided by Timothy Chan's group from Memorial Sloan-Kettering Cancer Center27 and 
Paul Khavari's group from Veterans Affairs Palo Alto Healthcare System24, respectively. 
Both ORFs were sub-cloned into lentiviral based expression vector SHC003 (Sigma-
Aldrich) using Nhe I and Fse I cloning sites. SHC003-Turbo-GFP was used as control 
(Sigma-Aldrich). The lentiviral based shRNA vectors (shXPO1 and shFAT2 sequences are 
listed in Supplementary Table 13b) were generated with PLKO.1 backbone (Sigma-Aldrich) 
using Age I and EcoR I cloning sites. SHC002-Scramble shRNA was used as control 
(Sigma-Aldrich). The cloning primers are listed in Supplementary Table 13c.
Transfections, viral particle production and infection
ESCC cells and 293T cells were transfected with Lipofectamine 2000 according to the 
manufacturer's instructions (Invitrogen). siRNA sequences targeting FAT1 or ZNF750 are 
listed in Supplementary Table 13d. Lentiviral particles were produced and harvested using 
MISSION Lentiviral Packaging System (Sigma-Aldrich). The ESCC cells were infected 
with the lentiviral particles for 48 hours in the presence of 8 ug/ml polybrene (Sigma-
Aldrich).
Whole exome sequencing (WES) and targeted deep sequencing (TDS)
1.5 μg (WES)or 1 μg (TDS) of genomic DNA was sonicated to generate a peak target size of 
200 bp. DNA was captured using the SureSelect® Human All Exon 50M (WES) or 
customized cRNA beads (Supplementary Table 14, TDS) according to the manufacturers' 
protocols. Captured DNAs were subjected to massively parallel sequencing using 
HiSeq2000 with 75-100 bp paired-end reads.
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To detect somatic nucleotide variations from WES, the previously described in-house 
algorithms were used57-59. Briefly, the sequencing reads were aligned to a human reference 
genome (hg19) using BWA version 0.5.8 with default parameters. PCR duplicate reads were 
removed using Picard (http://www.picard.sourceforge.net/). Before summarizing base call 
data, low quality reads were eliminated, including those reads which have either more than 5 
mismatches to the reference sequences or whose mapping quality was less than 30. The 
significance of each candidate mutation was evaluated by Fisher's exact test by enumerating 
the number of the reference base and the candidate SNV in both tumor and germline control. 
Candidate mutations with p-values less than 0.01 were adopted as provisional candidates for 
somatic mutations. In addition, the following nucleotide positions were eliminated from 
further analysis, including those positions at which the depth is less than 10 in either tumor 
or control, or the most frequent SNV or indel accounts for less than 7% of all reads in the 
tumor. Germline SNPs were eliminated using sequencing data from paired normal DNA. 
Finally, a list of candidate somatic mutations was generated by excluding synonymous 
SNVs and other variants registered in dbSNP131, 1,000 genomes, or our in-house SNP 
database constructed from 180 patients57,58.
To make a more rigorous somatic mutation calling with the TDS approach of Frequency 
Cohort, the following nucleotide positions were further removed: the supporting depth from 
both directions was less than 5 in either tumor or control, or the most frequent SNV or indel 
accounts for less than 8% of all reads in the tumor.
To detect probable somatic mutations of ESCC cell lines which do not have paired germline 
controls, the following nucleotide positions were further removed: the supporting depth 
from both directions is less than 5, or the most frequent SNV or indel accounts for less than 
8% of all reads, or the frequency of the SNV or indel is between 45% and 55% without copy 
number abnormalities.
Tissue microarray (TMAs) and immunohistochemistry (IHC)
Paraffin-embedded tissue microarrays (TMAs) containing 50 primary ESCC tumors and the 
corresponding normal epithelia were used for IHC. For each case, histologically normal 
tissues adjacent to tumors were examined as control. TMA slides were initially 
deparaffinized using xylene, rehydrated with xylene and ethanol, immersed in 3% hydrogen 
peroxide solution for 10 min, heated with citrate at 95°C for 25 min, and cooled at room 
temperature for 60 min. The slides were incubated overnight at 4°C with the following 
antibodies: XPO1 (sc-5595, Santa Cruz Biotechnology; 1:50), ZNF750 (HPA023012, 
Sigma-Aldrich Inc.; 1:100), FAT1 (HPA023882, Sigma-Aldrich Inc.; 1:25), or FBXW7 
(H00055294-M02, Abnova; 1:200), FGFR1 (9740, Cell Signaling Technology, 1:25) and 
visualized using PV-9000 Polymer Detection System following the manufacturer's 
instructions (Golden Bridge International, USA). Counterstaining was carried out with 
hematoxylin. The results were separately evaluated by two pathologists. Protein expression 
was evaluated on the basis of staining intensity, graded on the following scale: 0 (negative), 
1 (weak), 2 (moderate), and 3 (strong).
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Western blotting (WB)
Cells were lysed on ice with lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mMNaCl, 0.5% 
Nonidet P-40) containing complete protease and phosphatase inhibitor cocktail (Roche). The 
rest procedures for WB was performed as described previously60. Antibodies specific for 
cyclin B1 (4135), cleaved-PARP (9541), p21WAF1(2947) and BIM (2933) were purchased 
from Cell Signaling Technology. Antibodies specific for c-Myc (SC-788), cyclin D1 
(sc-8396), Bcl-xl (sc-8392), P53 (sc-6243), XPO1 (sc-5595) and PUMA (sc-28226) were 
purchased from Santa Cruz Biotechnology. Antibody against FAT1 (HPA023882), ZNF750 
(HPA023012) and β-Actin (A5316) were purchased from Sigma-Aldrich.
RNA extraction and paired-end sequencing
6 μg of total RNA from each sample was extracted according to the manufacturer's 
instruction of RNeasy Micro kit (QIAGEN, Germany), followed by mRNA purification 
using Oligotex mRNA Mini Kit (QIAGEN, Germany). RNA quality was assessed by 
Agilent 2100 Bioanalyzer, and the RNA integrity number was > 7.0, with 28S/18S > 0.7. 
The cDNA libraries were constructed following the TruSeq RNA Sample Preparation Guide 
(Illumina, USA). Briefly, first-strand and second-strand cDNAs were synthesized from the 
purified mRNAs, and fragmented by ultrasonic waves. After performing end repair, cDNAs 
were modified by 3′-end adenylation and adaptor ligation. PCR was performed to enrich the 
cDNA templates in order to complete the cDNA library construction. The concentration of 
the final cDNA library was more than 1 ng/μl, and the size of the cDNA fragments was 
350-400 bp. Sequencing reagents were prepared according to the Genome Analyzer IIx User 
Guide (Illumina). cDNA fragments were treated with cluster generation and loaded to the 
lanes of Illumina flow cells, and paired-end sequencing was performed using the 2×100 nt 
multiplex program. The raw sequenced reads yielded more than 50 million bases per sample.
Array-based CGH and SNP-array
Array-CGH experiments were performed using standard protocols as previously described 
(44K human genome CGH microarrays, Agilent Technologies, Santa Clara, CA)9. Human 
genomic DNA (PROMEGA, Warrington, UK) was used as reference. Briefly, 500 ng of 
reference genomic DNA and tumor DNA were digested with Alu I and Rsa I (PROMEGA, 
Warrington, UK). The resulting reference DNA was labeled with cyanine-5 dUTP and the 
tumor DNA with cyanine-3 dUTP, respectively (Agilent Technologies, Santa Clara, CA). 
After clean-up, labeled DNA probes were mixed and hybridized to CGH microarray for 
24h-40h. Washing, scanning and data extraction were performed according to standard 
protocols. Array CGH data were analyzed using Genomic Workbench (Agilent), BRB-CGH 
tools and MD-SeeGH (See URL). Mean log2 tumor/reference ratio of all probes in a 
chromosome region > 1.0 was determined as high-amplitude amplification, and < -1.0 as 
high-amplitude deletion. These values were converted based on the following presumptions: 
(i) for amplifications, copy number > 6 was present in more than 70% cancer cell 
populations; (ii) for deletions, loss of both alleles was present in more than 70% cancer cell 
populations, and (iii) normal cell contamination was less than 30%60.
Human 250K arrays (Affymetrix) were used for SNP-array assays, and results were 
analyzed as previously described using CNAG/AsCNAR software61,62.
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Interphase cell nuclei preparations and fluorescence in situ hybridization (FISH)
In order to examine interphase cell nuclei, ESCC tissue samples were cut into small pieces 
in phosphate-buffered saline (PBS), followed by treatment with a hypotonic solution (0.075 
mol/L KCl) for 30 minutes and three successive changes of the fixative solution (methanol/
acetic acid, 3:1). Interphase cell nuclei in suspension were kept at 4°C overnight and then 
stored at -20°C. Prior to the hybridization, the nuclear suspensions were dropped onto slides 
and dried at room temperature for 2-3 days.
FISH was performed on the interphase cell nuclei. By random priming using BioPrime DNA 
labeling system (Invitrogen), chromosome enumeration probes (CEP) and bacterial artificial 
chromosome (BAC)-DNA probes were directly labeled with Green-dUTP (Abbott 
Molecular, USA) and Cy3-dUTP (GE Healthcare, USA), respectively. BAC-DNA clones 
selected for FGFR1 were NONSC11F1 (Chr8: 38,170,901-38,368,835).
The slides for FISH analyses were pretreated with RNase A (100 mg/ml in 2 × saline 
sodium citrate [SSC]) and pepsin (50 mg/ml in 0.01 mol/l HCl), subsequently denatured in 
70% formamide/2 × SSC at 73°C-75°C for 3 minutes, quickly cooled with two rinses of 2 × 
SSC at 4°C, dehydrated in a gradient series of ethanol (75%, 85% and 100%), and air dried. 
The labeled probes were precipitated, and re-dissolved in the hybridization solution (50% 
formamide, 10% dextran sulfate, 1% Tween-20, 2 × SSC), denatured at 75°C for 8 minutes, 
and quick-chilled on ice for 2 minutes. Hybridization was performed in a humid chamber at 
37°C for 24-48 hours. Post-hybridization washes were performed in 50% formamide/2 × 
SSC for 15 minutes at 43°C and were performed twice for 3 minutes each in 2 × SSC. The 
slides were dehydrated in 75%, 85% and 100% ethanol, air dried, counterstained with 40,6-
diamidino-2-phenylindole (DAPI) (1 mg/ml) and covered with coverslips.
Microscopy and digital image analysis
FISH images were captured using a Zeiss Axio fluorescence microscope equipped with a 
cooled charged-coupled device (CCD) camera (Princeton Instruments, USA) or a JAI M4 
Plus CCD camera (Metasystems International, Germany). All of the fluorescent images were 
captured with individual single-band-pass filters specific for visualizing DAPI, Green, Cy3 
fluorochromes. Pseudo-color images were constructed and analyzed using MetaMorph 
(Universal Imaging Corporation, USA) or Metacyte module of Metafer imaging systems 
(Metasystems International).
Amplifications were assessed as the difference value between BAC-DNA and CEP probes 
was at least 2 in more than 30% cells. Cluster signals and ratios (BAC-DNA/CEP) > 2 were 
judged as the high-level amplifications.
Analysis of significantly altered pathways
To analyze significantly altered pathways, we performed unbiased Gene Ontology (GO) 
enrichment in the overall ranked MutSigCV list63. As parallel approaches, WEB-based 
Gene SeT AnaLysis Toolkit (WebGestalt) was applied to identify the KEGG pathways that 
are enriched in the MutSigCV list. Multiple-test corrected P-values were calculated using 
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hypergeometric test for pathways that are enriched compared to human genome reference 
gene set64,65.
Statistical analysis
Q value for significantly mutated genes were calculated using default setting according to 
MutSigCV13. The p value of the two mutational events as mutually exclusive events is 
defined by calculating the joint probability. The statistical analyses of the following assays 
were conducted using the two tailed Student's t-test upon verification of the assumptions 
(e.g., normality), otherwise the non-parametric test was applied: short-term cell 
proliferation, xenografts proliferation, q-PCR, apoptosis induction, mRNA levels examined 
from GSE2034711, GSE2340054 and CCLE.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutation frequencies and signatures, and significantly mutated genes in 139 ESCCs
(a) The number of somatic mutations of each examined case (top), key clinical parameters 
(middle, see Supplementary Tables 2a and 2b), and the significantly mutated genes (SMG) 
colored by the type of mutations and their mutational frequency (bottom). Columns, 
examined cases; Rows, genes. (b) Trinucleotide contexts of mutations occurring at cytosine 
nucleotides in ESCC. Font size of the bases at the 5′ and 3′ positions are proportional to 
their frequencies (see Supplementary Fig. 3b). (c) APOBEC3B mRNA levels calculated 
from two datasets GSE2034711 and GSE2340054, both of which examined cDNA 
microarray from matched normal/tumor ESCC cases.
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Figure 2. Dysregulated pathways in ESCC
(a) Representative FISH photos of an ESCC case with amplified FGFR1. Green signals 
label the centromere 8 probe (CNE8) and red signals label FGFR1 gene probe. Scale bars, 5 
μm. (b) Representative IHC photos of FGFR1 protein over-expression in ESCCs (Additional 
Cohort, 60 cases had matched adjacent normal epithelial tissues, see Supplementary Table 
8a). Scale bars, 200 μm. (c) Top panel, schematics of protein alterations in FBXW7 caused 
by somatic mutations. Black, missense; red, stopgain (X) or frameshift indel (fs); *, 
discovered by Agrawal et al.8. Conserved domains were mapped from UniProt (See URL). 
Bottom panel, representative FBXW7 IHC results of an ESCC case carrying FBXW7 
mutations (Frequency and Additional Cohort, all cases had matched adjacent normal 
epithelial tissue, see Supplementary Table 8b). Scale bars, 100 μm. (d-f) Significantly 
dysregulated pathways colored by the type of alterations. Red font denotes a predicted 
activating alteration; black font denotes a predicted inactivating alteration. (d) RTK-MAPK-
PI3K signaling; (e) G1-S cell cycle regulation; (f) Epigenetic modification.
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Figure 3. Indentification of ZNF750 as a novel recessive cancer gene in ESCC
(a) Schematics of protein alterations in ZNF750 caused by somatic mutations. Black, 
missense or inframe (inf); red, stopgain (X); *, discovered by Agrawal et al.8. Conserved 
domains were mapped from UniProt. (b) Top, IGV (Integrative Genomics Viewer) heatmap 
showing loss of ZNF750 copy number identified from 149 ESCC SNP-array data; Bottom, 
segmentation map of two tumors with ZNF750 deletions from 59 ESCCs examined with 
array-CGH. (c) ZNF750 mRNA levels calculated from GSE2034711 and GSE2340054. (d) 
Representative IHC photos of ZNF750 protein expression in ESCCs (Additional Cohort, all 
cases had matched adjacent normal epithelial tissues, see Supplementary Table 8c). Scale 
bars, 400 μm. (e) Short-term cell proliferations assays of EC109 and KYSE30 cells 
transfected with either siRNAs against ZNF750 (si-ZNF750) or control siRNA (Scramble). 
Data represent mean ± SD; N = 3. (f) ESCC cells were treated with TPA (100nM) for 24 
hours and lysates were subjected to WB analysis. (g) Under TPA (100nM) treatment, short-
term cell proliferations assay of KYSE30 cells ectopically expressing either GFP or ZNF750 
proteins. Data represent mean ± SD; N = 3. Blots of (e) and (g) showed the WB results of 
ZNF750 protein expression in indicated samples. β-Actin was examined as a loading 
control. *, P < 0.05.
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Figure 4. Inactivation of FAT1 through multiple mechanisms
(a) Schematics of protein alterations in FAT1, FAT2 and FAT3 caused by somatic 
mutations. Black, missense; red, stopgain (X), Splicing site (sp) or frameshift indel (fs); *, 
discovered by Agrawal et al.8. Conserved domains were mapped from UniProt. (b) Mutually 
exclusive analysis of FAT1, FAT2 and FAT3 mutations. Columns, examined cases; Rows, 
genes; Black, missense; red, stopgain, Splicing site or frameshift indel; *, P <0.01. (c) Top, 
IGV heatmap showing loss of FAT1 copy number identifiedfrom 149 ESCC SNP-array data; 
Bottom, segmentation map of two tumors with FAT1 deletions from 59 ESCC array-CGH 
data. (d) Representative IHC photos of FAT1 protein expression in ESCCs (Additional 
Cohort, all 18 cases had matched adjacent normal epithelial tissues, see Supplementary 
Table 8e). Scale bars, 400 μm. (e) Short-term cell proliferations were measured in EC109 
and KYSE150 cells transfected with either siRNAs against FAT1 (si-FAT1) or control 
(Scramble). Value represent mean ± SD; N = 4. Blots showed the WB results of FAT1 
protein level in indicated samples. β-Actin was detected as a loading control. (f) KYSE150 
cells stably expressing either control shRNA (Scramble) or shRNA targeting FAT2 
(shFAT2) were injected subcutaneously on the upper flanks of NOD/SCID mice. After 19 
days, mice were sacrificed, and the tumors were analyzed. (g) Relative levels of mRNAs of 
FAT2 quantified with q-PCR in either Scramble or shFAT2 KYSE150 cells. Value represent 
mean ± SD; N = 3.*, P< 0.05.
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Figure 5. Targeting XPO1 in ESCC
(a) Crystal structural modeling of D624G mutation in XPO1 protein (grey ribbon) and its 
relationship with Snurportin (red ribbon). Dashed yellow lines represent hydrogen bonds. (b) 
Representative IHC photos of XPO1 protein expression in ESCCs (ESCC-D18 was from 
Discovery Cohort; the rest of the cases were from Additional Cohort, all cases had matched 
adjacent normal epithelial tissues, see Supplementary Table 8d). Scale bars, 200 μm. (c) 
XPO1 mRNA levels examined from GSE2034711 and GSE2340054. (d) ESCC cells were 
infected with lentivirus encoding shRNA against either XPO1 (shXPO1) or control shRNA 
(Scramble), and their proliferation was measured, and (e) cell lysates were subjected to WB 
analysis with indicated antibodies. (f) ESCC cells were treated with KPT-330 at indicated 
concentrations for 72 hours, and cell proliferation and apoptosis (g) were measured, and (h) 
cell lysates were subjected to WB analysis with indicated antibodies. β-Actin was assayed as 
a loading control. Values of (d, f, g) represent mean ± SD. N = 4. **, P < 0.01; *, P < 0.05.
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